PROMETHEUS BIOSCIENCES, INC. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
PROMETHEUS BIOSCIENCES, INC. reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$123.25 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2023-02-28
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2021-12-31 was -$22.18M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2021-09-30 was -$16.98M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2021-06-30 was -$5.36M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2021-03-31 was -$18.99M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2022 was -$123.25M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2021 was -$63.51M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2020 was -$29.93M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$123.25M 10-K · filed 2023-02-28 | |||
| 2021-12-31 | -$22.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$39.15M derived: sum of 2 quarters · filed 2023-02-28 | -$44.51M derived: sum of 3 quarters · filed 2023-02-28 | -$63.51M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$16.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$22.33M derived: sum of 2 quarters · filed 2021-11-12 | -$41.33M 10-Q · filed 2021-11-12 | -$49.75M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$5.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$24.35M 10-Q · filed 2021-08-11 | -$32.77M derived: sum of 3 quarters · filed 2023-02-28 | -$38.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$18.99M 10-Q · filed 2021-05-13 | -$27.41M derived: sum of 2 quarters · filed 2023-02-28 | -$33.35M derived: sum of 3 quarters · filed 2023-02-28 | -$44.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$14.35M derived: sum of 2 quarters · filed 2023-02-28 | -$25.68M derived: sum of 3 quarters · filed 2023-02-28 | -$29.93M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$17.26M derived: sum of 2 quarters · filed 2021-11-12 | -$21.51M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$11.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$15.58M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$4.25M 10-Q · filed 2021-05-13 |